Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy
- PMID: 27325475
- DOI: 10.1016/j.ijrobp.2016.03.047
Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy
Abstract
Purpose: Severe urinary adverse events (UAEs) include surgical treatment of urethral stricture, urinary incontinence, and radiation cystitis. We compared the incidence of grade 3 UAEs, according to the Common Terminology Criteria for Adverse Events, after low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy, as well as after LDR plus external beam radiation therapy (EBRT) and HDR plus EBRT.
Methods and materials: Men aged >65 years with nonmetastatic prostate cancer were identified from the Surveillance, Epidemiology, and End Results-Medicare database who were treated with LDR (n=12,801), HDR (n=685), LDR plus EBRT (n=8518), or HDR plus EBRT (n=2392). The populations were balanced by propensity weighting, and the Kaplan-Meier incidence of severe UAEs was compared. Propensity-weighted Cox proportional hazards models were used to compare the adjusted hazard of UAEs. These UAEs were compared with those in a cohort of men not treated for prostate cancer.
Results: Median follow-up was 4.3 years. At 8 years, the propensity-weighted cumulative UAE incidence was highest after HDR plus EBRT (26.6% [95% confidence interval, 23.8%-29.7%]) and lowest after LDR (15.7% [95% confidence interval, 14.8%-16.6%]). The absolute excess risk over nontreated controls at 8 years was 1.9%, 3.8%, 8.4%, and 12.9% for LDR, HDR, LDR plus EBRT, and HDR plus EBRT, respectively. These represent numbers needed to harm of 53, 26, 12, and 8 persons, respectively. The additional risk of development of a UAE related to treatment for LDR, LDR plus EBRT, and HDR plus EBRT was greatest within the 2 years after treatment and then continued to decline over time. Beyond 4 years, the risk of development of a new severe UAE matched the baseline risk of the control population for all treatments.
Conclusions: Toxicity differences were observed between LDR and HDR, but the differences did not meet statistical significance. However, combination radiation therapy (either HDR plus EBRT or LDR plus EBRT) increases the risk of severe UAEs compared with HDR alone or LDR alone. The highest increased risk of urinary toxicity occurs within the 2 years after therapy and then declines to an approximately 1% increase in incidence per year.
Copyright © 2016. Published by Elsevier Inc.
Similar articles
-
Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.Eur Urol. 2015 Feb;67(2):273-80. doi: 10.1016/j.eururo.2014.08.061. Epub 2014 Sep 10. Eur Urol. 2015. PMID: 25217421
-
Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer.BJU Int. 2017 May;119(5):700-708. doi: 10.1111/bju.13607. Epub 2016 Aug 30. BJU Int. 2017. PMID: 27469289
-
Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):505-16. doi: 10.1016/j.ijrobp.2014.11.018. Epub 2015 Jan 13. Int J Radiat Oncol Biol Phys. 2015. PMID: 25596107
-
Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?Clin Oncol (R Coll Radiol). 2013 Aug;25(8):474-82. doi: 10.1016/j.clon.2013.04.009. Epub 2013 May 30. Clin Oncol (R Coll Radiol). 2013. PMID: 23727431 Review.
-
[Brachytherapy in men with prostate cancer: update on indications and outcomes].Urologia. 2013 Apr-Jun;80(2):87-98. doi: 10.5301/RU.2013.11285. Epub 2013 Jul 1. Urologia. 2013. PMID: 23852925 Review. Italian.
Cited by
-
Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review.J Contemp Brachytherapy. 2020 Apr;12(2):181-187. doi: 10.5114/jcb.2020.94585. Epub 2020 Apr 30. J Contemp Brachytherapy. 2020. PMID: 32395143 Free PMC article.
-
Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials.J Contemp Brachytherapy. 2017 Oct;9(5):403-409. doi: 10.5114/jcb.2017.70763. Epub 2017 Oct 19. J Contemp Brachytherapy. 2017. PMID: 29204160 Free PMC article.
-
Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions.Front Oncol. 2021 Sep 30;11:717180. doi: 10.3389/fonc.2021.717180. eCollection 2021. Front Oncol. 2021. PMID: 34660280 Free PMC article. Review.
-
Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):116-126. doi: 10.1016/j.ijrobp.2018.05.043. Epub 2018 Jun 1. Int J Radiat Oncol Biol Phys. 2018. PMID: 30102188 Free PMC article.
-
A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.Front Oncol. 2019 Dec 10;9:1378. doi: 10.3389/fonc.2019.01378. eCollection 2019. Front Oncol. 2019. PMID: 31921640 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical